Discovery of triterpenoids as potent dual inhibitors of pancreatic lipase and human carboxylesterase 1

References

• Malik V, Willett W, Hu F. Global obesity: trends, risk factors and policy implications. Nat Rev Endocrinol 2013;9:13–27.
   PubMed Web of Science ®Google Scholar
• Mameli C, Zuccotti G, Carnovale C, et al. An update on the assessment and management of metabolic syndrome, a growing medical emergency in paediatric populations. Pharmacol Res 2017;119:99–117.
   PubMed Web of Science ®Google Scholar
• Motamed N, Rabiee B, Roozafzai F, et al. Metabolic syndrome and cardiovascular risk assessment tools' estimations of 10-year cardiovascular risk: a population-based study. Acta Cardiol 2018;73:439–46.
   PubMed Web of Science ®Google Scholar
• Ménégaut L, Thomas C, Lagrost L, Masson D. Fatty acid metabolism in macrophages: a target in cardio-metabolic diseases. Curr Opin Lipidol 2017;28:19–26.
   PubMed Web of Science ®Google Scholar
• Danaei G, Ding E, Mozaffarian D, et al. The preventable causes of death in the United States: comparative risk assessment of dietary, lifestyle, and metabolic risk factors. PLoS Med 2009;6:e1000058.
   PubMed Web of Science ®Google Scholar
• Xiao D, Chen Y, Yang D, Yan B. Age-related inducibility of carboxylesterases by the antiepileptic agent phenobarbital and implications in drug metabolism and lipid accumulation. Biochem Pharmacol 2012;84:232–9.
   PubMed Web of Science ®Google Scholar
• Merali Z, Ross S, Paré G. The pharmacogenetics of carboxylesterases: CES1 and CES2 genetic variants and their clinical effect. Drug Metab Drug Interact 2014;29:143–51.
   PubMedGoogle Scholar
• Hatfield M, Umans R, Hyatt J, et al. Carboxylesterases: general detoxifying enzymes. Chem-Biol Interact 2016;259:327–31.
   PubMed Web of Science ®Google Scholar
• Wang D, Zou L, Jin Q, et al. Human carboxylesterases: a comprehensive review. Acta Pharm Sin. B 2018;8:699–712.
   PubMed Web of Science ®Google Scholar
• Lian J, Nelson R, Lehner R. Carboxylesterases in lipid metabolism: from mouse to human. Protein Cell 2018;9:178–95.
   PubMed Web of Science ®Google Scholar
• Zou L, Jin Q, Wang D, et al. Carboxylesterase inhibitors: an update. Curr Med Chem 2018;25:1627–49.
   PubMed Web of Science ®Google Scholar
• Ross M, Crow J. Human carboxylesterases and their role in xenobiotic and endobiotic metabolism. J Biochem Mol Toxicol 2007;21:187–96.
   PubMed Web of Science ®Google Scholar
• Laizure S, Herring V, Hu Z, et al. The role of human carboxylesterases in drug metabolism: have we overlooked their importance? Pharmacotherapy 2013;33:210–22.
   PubMed Web of Science ®Google Scholar
• Tarkiainen EK, Holmberg MT, Tornio A, et al. Carboxylesterase 1 c.428G>A single nucleotide variation increases the antiplatelet effects of clopidogrel by reducing its hydrolysis in humans. Clin Pharmacol Ther 2015;97:650–8.
   PubMed Web of Science ®Google Scholar
• Shi D, Yang J, Yang D, et al. Anti-influenza prodrug oseltamivir is activated by carboxylesterase human carboxylesterase 1, and the activation is inhibited by antiplatelet agent clopidogrel. J Pharmacol Exp Ther 2006;319:1477–84.
   PubMed Web of Science ®Google Scholar
• Zou LW, Li YG, Wang P, et al. Design, synthesis, and structure-activity relationship study of glycyrrhetinic acid derivatives as potent and selective inhibitors against human carboxylesterase 2. Eur J Med Chem 2016;112:280–8.
   PubMed Web of Science ®Google Scholar
• Zou LW, Dou TY, Wang P, et al. Structure–activity relationships of pentacyclic triterpenoids as potent and selective inhibitors against human carboxylesterase 1. Front Pharmacol 2017;8:435.
   PubMed Web of Science ®Google Scholar
• Dominguez E, Galmozzi A, Chang J, et al. Integrated phenotypic and activity-based profiling links Ces3 to obesity and diabetes. Nat Chem Biol 2014;10:113–21.
   PubMed Web of Science ®Google Scholar
• Quiroga A, Li L, Trötzmüller M, et al. Deficiency of carboxylesterase 1/esterase-x results in obesity, hepatic steatosis, and hyperlipidemia. Hepatology (Baltimore, Md.) 2012;56:2188–98.
   PubMed Web of Science ®Google Scholar
• Wei E, Ben Ali Y, Lyon J, et al. Loss of TGH/Ces3 in mice decreases blood lipids, improves glucose tolerance, and increases energy expenditure. Cell Metab 2010;11:183–93.
   PubMed Web of Science ®Google Scholar
• Mukherjee S, Choi M, Yun JW. Novel regulatory roles of carboxylesterase 3 in lipid metabolism and browning in 3T3-L1 white adipocytes. Appl Physiol Nutr Metab 2019;44:1089–98.
   PubMed Web of Science ®Google Scholar
• Ashla A, Hoshikawa Y, Tsuchiya H, et al. Genetic analysis of expression profile involved in retinoid metabolism in non-alcoholic fatty liver disease. Hepatol Res 2010;40:594–604.
   PubMed Web of Science ®Google Scholar
• Nagashima S, Yagyu H, Takahashi N, et al. Depot-specific expression of lipolytic genes in human adipose tissues-association among CES1 expression, triglyceride lipase activity and adiposity. J Atheroscler Thromb 2011;18:190–9.
   PubMed Web of Science ®Google Scholar
• Gilham D, Ho S, Rasouli M, et al. Inhibitors of hepatic microsomal triacylglycerol hydrolase decrease very low density lipoprotein secretion. FASEB J: Off Publ Federation Am Soc Exp Biol 2003;17:1685–7.
   PubMed Web of Science ®Google Scholar
• Lian J, Bahitham W, Panigrahi R, et al. Genetic variation in human carboxylesterase CES1 confers resistance to hepatic steatosis. Biochimica Biophysica Acta. Mol Cell Biol Lipids 2018;1863:688–99.
   Google Scholar
• Bachovchin DA, Cravatt BF. The pharmacological landscape and therapeutic potential of serine hydrolases. Nat Rev Drug Discov 2012;11:52–68.
   PubMed Web of Science ®Google Scholar
• Birari RB, Bhutani KK. Pancreatic lipase inhibitors from natural sources: unexplored potential. Drug Discov Today 2007;12:879–89.
   PubMed Web of Science ®Google Scholar
• Sukhdev S, Bhupender S, Singh KS. Pharmacotherapy & surgical interventions available for obesity management and importance of pancreatic lipase inhibitory phytomolecules as safer anti-obesity therapeutics. Mini Rev Med Chem 2017;17:371–9.
   PubMed Web of Science ®Google Scholar
• Houghton D, Wilcox MD, Chater PI, et al. Biological activity of alginate and its effect on pancreatic lipase inhibition as a potential treatment for obesity. Food Hydrocoll 2015;49:18–24.
   PubMed Web of Science ®Google Scholar
• de la Garza AL, Milagro FI, Boque N, et al. Natural inhibitors of pancreatic lipase as new players in obesity treatment. Planta Med 2011;77:773–85.
   PubMed Web of Science ®Google Scholar
• Wang DD, Zou LW, Jin Q, et al. Recent progress in the discovery of natural inhibitors against human carboxylesterases. Fitoterapia 2017;117:84–95.
   PubMed Web of Science ®Google Scholar
• Zhao YS, Qian XK, Guan XQ, et al. Discovery of natural alkaloids as potent and selective inhibitors against human carboxylesterase 2. Bioorg Chem 2020;105:104367.
   PubMed Web of Science ®Google Scholar
• Song PF, Zhu YD, Ma HY, et al. Discovery of natural pentacyclic triterpenoids as potent and selective inhibitors against human carboxylesterase 1. Fitoterapia 2019;137:104199.
   PubMed Web of Science ®Google Scholar
• Neovius M, Johansson K, Rössner S. Head-to-head studies evaluating efficacy of pharmaco-therapy for obesity: a systematic review and meta-analysis. Obes Rev 2008;9:420–7.
   PubMed Web of Science ®Google Scholar
• Kaila B, Raman M. Obesity: a review of pathogenesis and management strategies. Can J Gastroenterol 2008;22:61–8.
   PubMed Web of Science ®Google Scholar
• Chauhan D, George G, Sridhar SNC, et al. Design, synthesis, biological evaluation, and molecular modeling studies of rhodanine derivatives as pancreatic lipase inhibitors. Arch Pharm 2019;352:e1900029.
   PubMed Web of Science ®Google Scholar
• Hodon J, Borkova L, Pokorny J, et al. Design and synthesis of pentacyclic triterpene conjugates and their use in medicinal research. Eur J Med Chem 2019;182:111653.
   PubMed Web of Science ®Google Scholar
• Hill RA, Connolly JD. Triterpenoids. Nat Prod Rep 2017;34:90–122.
   PubMed Web of Science ®Google Scholar
• Dzubak P, Hajduch M, Vydra D, et al. Pharmacological activities of natural triterpenoids and their therapeutic implications. Nat Prod Rep 2006;23:394–411.
   PubMed Web of Science ®Google Scholar
• Salvador JAR, Leal AS, Valdeira AS, et al. Oleanane-, ursane-, and quinone methide friedelane-type triterpenoid derivatives: recent advances in cancer treatment. Eur J Med Chem 2017;142:95–130.
   PubMed Web of Science ®Google Scholar
• Xiao S, Tian Z, Wang Y, et al. Recent progress in the antiviral activity and mechanism study of pentacyclic triterpenoids and their derivatives. Med Res Rev 2018;38:951–76.
   PubMed Web of Science ®Google Scholar
• Wu P, Zheng J, Huang T, et al. Synthesis and evaluation of novel triterpene analogues of ursolic acid as potential antidiabetic agent. PLoS One 2015;10:e0138767.
   PubMed Web of Science ®Google Scholar
• Ding YJ, Sun CY, Wen CC, Chen YH. Nephroprotective role of resveratrol and ursolic acid in aristolochic acid intoxicated zebrafish. Toxins (Basel 2015;7:97–109.
   PubMed Web of Science ®Google Scholar
• Hu Q, Guan XQ, Song LL, et al. Inhibition of pancreatic lipase by environmental xenoestrogens. Ecotoxicol Environ Saf 2020;192:110305.
   PubMed Web of Science ®Google Scholar
• Wang DD, Zou LW, Jin Q, et al. Bioluminescent sensor reveals that carboxylesterase 1A is a novel endoplasmic reticulum-derived serologic indicator for hepatocyte injury. ACS Sens 2020;5:1987–95.
   PubMed Web of Science ®Google Scholar
• Liu PK, Weng ZM, Ge GB, et al. Biflavones from Ginkgo biloba as novel pancreatic lipase inhibitors: inhibition potentials and mechanism. Int J Biol Macromol 2018;118:2216–23.
   PubMed Web of Science ®Google Scholar
• Zhang J, Yang Y, Qian XK, et al. Design, synthesis, and structure–activity relationship study of pyrazolones as potent inhibitors of pancreatic lipase. ChemMedChem 2021;16:1600–4.
   PubMed Web of Science ®Google Scholar
• Qian XK, Zhang J, Li XD, et al. Research progress on dipeptidyl peptidase family: structure, function and xenobiotic metabolism. Curr Med Chem 2021. DOI:10.2174/0929867328666210915103431.
   Google Scholar
• Zhang J, Qian XK, Song PF, et al. A high-throughput screening assay for dipeptidyl peptidase-IV inhibitors using human plasma. Anal Methods 2021;13:2671–8.
   PubMed Web of Science ®Google Scholar
• Ma H, Qian X-K, Zhang J, et al. Accurate and sensitive detection of dipeptidyl peptidase-IV activity by liquid chromatography with fluorescence detection. Anal Methods 2020;12:848–54.
   Web of Science ®Google Scholar
• Trott O, Olson AJ. AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J Comput Chem 2010;31:455–61.
   PubMed Web of Science ®Google Scholar
• Martinez-Gonzalez AI, Alvarez-Parrilla E, Díaz-Sánchez ÁG, et al. In vitro inhibition of pancreatic lipase by polyphenols: a kinetic, fluorescence spectroscopy and molecular docking study. Food Technol Biotechnol 2017;55:519–30.
   PubMed Web of Science ®Google Scholar
• Wang L, Guan XQ, He RJ, et al. Pentacyclic triterpenoid acids in Styrax as potent and highly specific inhibitors against human carboxylesterase 1A. Food Funct 2020;11:8680–93.
   PubMed Web of Science ®Google Scholar
• Qian XK, Zhang J, Song PF, et al. Discovery of pyrazolones as novel carboxylesterase 2 inhibitors that potently inhibit the adipogenesis in cells. Bioorg Med Chem 2021;40:116187.
   PubMed Web of Science ®Google Scholar